Create a narrative

AtriCure Community

NasdaqGM:ATRC Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 9 Analysts

AtriClip Devices And LeAAPS Trial Will Expand Market Reach

Key Takeaways New product launches and clinical trials could enhance market penetration, positioning AtriCure as a leader in stroke reduction and atrial fibrillation treatment. Expansion in pain management and operational efficiencies contribute to significant revenue growth, potentially improving margins and profitability.

US$52.22

FV

42.0% undervalued

12.77%

Revenue growth p.a.

0

0

2

7 days ago